NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2001 (First Quarter of Fiscal 2002)
Business Overview: The Company operates in the dietary supplement industry, focusing on private label contract manufacturing ("core business") and direct-to-consumer ("DTC") products. Operations are split between U.S. facilities in San Marcos, California, and a Swiss subsidiary (NAIE).

Key Financial Metrics

Note: Debt figures derived from Balance Sheet line items (Lines of credit, Current installments of long-term debt, Long-term debt). Working Capital calculated as Current Assets ($12,475) minus Current Liabilities ($7,616).

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 3% ($336,000) year-over-year. The core contract manufacturing business declined, while DTC sales doubled to $2.0 million due to new product introductions.
• Profitability Reversal: The Company shifted from a net income of $205,000 in Q1 2001 to a net loss of $658,000 in Q1 2002. This was driven by a $1.2 million increase in Selling, General, and Administrative (SG&A) expenses, which rose to 25% of sales from 15% in the prior year.
• Expense Drivers: Increased SG&A was attributed to legal expenses ($273,000), separation expenses ($150,000), and DTC promotional costs ($432,000). Legal expenses were partially offset by $129,000 in insurance proceeds.
• Customer Concentration: Sales to the top four customers accounted for 75% of total revenue. Sales to the third and fourth largest customers declined significantly due to inventory adjustments and product mix shifts.
• Cash Flow: Operating activities used $477,000 in cash, compared to providing $433,000 in the prior year. Financing activities provided $1.036 million, primarily through increased borrowings on lines of credit.

Guidance, Outlook, and Risks

• Debt Covenant Compliance: The Company was not in compliance with financial covenants as of June 30, 2001. In October 2001, the credit agreement was amended to waive defaults, reduce the working capital line to $2.5 million, and increase the interest rate to prime plus 3.5%. The Company is currently compliant under the amended terms.
• Liquidity: Management believes available cash ($792,000) and existing credit facilities (approx. $3.8 million total access) are sufficient for near-term operations. Excess borrowing capacity based on eligible collateral is approximately $2.1 million.
• Legal Proceedings: The Company is a plaintiff in the In re: Vitamin Antitrust Litigation, having received $416,000 in settlement payments to date. A lawsuit with a former executive was settled and dismissed.
• Market Risks: Significant risks include reliance on a limited number of customers (75% of sales), potential for increased competition, regulatory changes by the FDA/FTC, and exposure to foreign exchange fluctuations (Swiss Franc debt).
• Outlook: Management expects operating results to fluctuate. There is no assurance that efforts to reverse sales declines will be effective or that profitability can be maintained.

Investor Verification Checklist

• Debt Covenant Status: Verify continued compliance with the amended credit agreement covenants (minimum tangible net worth, leverage ratios) to avoid default.
• Customer Retention: Monitor sales trends for the top four customers, particularly the third and fourth largest, given their recent volume declines.
• SG&A Control: Assess whether the elevated SG&A expenses (legal, separation, marketing) are one-time items or indicative of a new, higher cost structure.
• Antitrust Litigation: Track the status of the Vitamin Antitrust Litigation for potential additional recoveries or legal costs.
• Foreign Exchange Exposure: Evaluate the impact of Swiss Franc fluctuations on the $952,000 of Swiss-denominated debt and operations.